Ares Genetics, a unit of molecular diagnostics developer Curetis, has secured funding from the Vienna Business Agency to support the development of an artificial intelligence (AI)-based diagnostic test called ARESupa.

The ARESupa Universal Pathogenome Assay is being developed to detect infection-causing pathogens and related antibiotic resistance.

It will combine next-generation sequencing (NGS) technology with the company’s AI curated genetic pathogen and antibiotic resistance (AMR) reference database, ARESdb, to interpret results.

The test is part of the company’s TRIPLE-A (Assay Development and Artificial Intelligence to Diagnose Antibiotic Resistant Infections) development project, which is estimated to span over 2.5 years and cost approximately €1.3m.

Ares Genetics intends to design the test to detect nearly all types of pathogens and associated drug resistances using any native patient sample. Development of the assay was initiated in September last year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
“We are combining NGS technology and advanced data analytics based on our ARESdb database.”

The company will use the fresh funds to create a laboratory prototype of the AI-based diagnostic test.

It is building a dedicated research and development (R&D) and diagnostic service laboratory, dubbed ARESlab, in Vienna, Austria, to support in-house test development and initial commercialisation in Europe.

Ares Genetics managing director and CEO Andreas Posch said: “We are combining NGS technology and advanced data analytics based on our ARESdb database, which already today allows for quantitative molecular prediction of antibiotic resistance with up to more than 98% accuracy.”

Posch added that the company is looking to obtain venture capital funding in the US in order to further advance ARESupa development and commercial launch in the country.

Previously, Vienna Business Agency agreed to support the company’s ARES&CO Pharma Partnering Program.

Under the programme, Ares Genetics collaborated with Novartis division Sandoz to develop a digital anti-infectives platform.